How I manage ibrutinib-refractory chronic lymphocytic leukemia
Open Access
- 9 March 2017
- journal article
- case report
- Published by American Society of Hematology
- Vol. 129 (10), 1270-1274
- https://doi.org/10.1182/blood-2016-09-693598
Abstract
The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib has dramatically changed the management of chronic lymphocytic leukemia (CLL). Although responses have been durable in the majority of patients, relapses do occur, especially in the high-risk patient population. Most relapses occur as the result of acquired mutations in BTK and PLCG2, which may facilitate success with alternative targeted therapies. As outcomes after ibrutinib relapse have been reported to be poor, specific strategies are needed for this patient population. Here, I discuss the diagnosis and management of ibrutinib-refractory CLL. The focus will be on common clinical scenarios that can be mistaken for relapse and how to accurately determine which patients are relapsing. Because there is no established standard of care, I discuss currently available options for standard therapy and existing clinical data. I also discuss new agents with the potential to be effective in patients refractory to ibrutinib. Finally, I discuss strategies for long-term disease control in this patient population.Keywords
This publication has 31 references indexed in Scilit:
- Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitorsLeukemia, 2014
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481SBTKMutation Revealed by Longitudinal Functional Genomics in Mantle Cell LymphomaCancer Discovery, 2014
- PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLLBlood, 2014
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2014
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibNew England Journal of Medicine, 2014
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyBlood, 2014
- A Hypermorphic Missense Mutation in PLCG2 , Encoding Phospholipase Cγ2, Causes a Dominantly Inherited Autoinflammatory Disease with ImmunodeficiencyAmerican Journal of Human Genetics, 2012
- Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2012
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2010
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002